Key takeaways
Vumerity (diroximel fumarate) and Mayzent (siponimod) are both used to treat relapsing forms of multiple sclerosis (MS), but they work in different ways and have different dosing schedules. Vumerity is a fumaric acid derivative taken twice daily, while Mayzent is a sphingosine 1-phosphate receptor modulator taken once daily. Mayzent requires genetic testing before starting to determine the correct dose, which is not necessary for Vumerity. Vumerity's exact mechanism is unknown but is thought to reduce inflammation, whereas Mayzent blocks white blood cells from leaving lymph nodes, reducing nerve damage. Vumerity can cause side effects like flushing and stomach upset, while Mayzent can cause headaches, high blood pressure, and high liver enzyme levels. Both medications are only available as brand-name and can cause liver problems and serious infections. Additionally, Mayzent also increases the risk of skin cancer and can cause eye and breathing problems.
